Drug Trial Radar · NCT04408625
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Nov 9, 2020
Primary completion
Nov 30, 2029
Study completion Nov 30, 2029
Sponsor
- Lead sponsor
- Prevail TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- May 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884963 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will follow up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.
Conditions
- Frontotemporal Dementia
Interventions
LY3884963Biological
Participants will receive a single dose of LY3884963, administered intra cisterna magna
MethylprednisoloneDrug
IV pulses every 2 weeks in the first 3 months.
Optional SirolimusDrug
At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication
Optional PrednisoneDrug
If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuationTime frame: 5 Years
- Sum of adverse reactions (ARs) and suspected ARsTime frame: 5 years
- Sum of serious ARs and serious suspected ARsTime frame: 5 years
- Incidence of procedure or treatment-emergent AEsTime frame: 5 years
- Change in AAV9, PGRN, and NfL immunogenicity in bloodTime frame: Days 7, 14, and 21 and at Months 1, 1.5, 2, 3, 6, 9, 12, 18, and 24
- Change in AAV9, PGRN, and NfL immunogenicity in CSFTime frame: Months 2, 6, 12, 18, and 24
- Change in PGRN levels in bloodTime frame: Days 7, 14, and 21 and at Months 1, 1.5, 2, 3, 6, 9, 12, 18, and 24
- Change in PGRN levels in CSFTime frame: Months 2, 6, 12, 18, and 24
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
k2 Medical Research-Maitland
Maitland, Florida
PPD Phase 1 Clinic, 100 West Gore Street, Suite 202
Orlando, Florida
Lahey Hospital & Medical Center, 41 Burlington Mall Road
Burlington, Massachusetts
Hospital of the University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street
Philadelphia, Pennsylvania
Royal Prince Alfred Hospital, Brain & Mind Research Institute, 94 Mallet Street
Camperdown, New South Wales, Australia
UZ Leuven, Neurologie Herestraat 49
Leuven, Belgium
Centre Mémoire de Ressources
Lille, France
Le Ber, Institut du Cerveau et de la Moelle Epinière
Paris, France
AP-HM Hôpital de La Timone
Saint-Pierre, Marseille, France
Hospital Clinic de Barcelona, Villaroel 170 Servicio de Neurología
Barcelona, Spain
Hospital Universitario de Donostia, Servicio De Neurologia, Consultas Externas Neurologia, San Sebastian, Guipúzcoa
Donostia / San Sebastian, Spain
University College London,Queen Square, Dementia Research Building, London,
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.